GILD|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.15 | - | - |
| Q2'26 | $-7.38 | $-6.75 | +8.5% |
| Q1'26 | $1.95 | $2.03 | +4.0% |
| Q4'25 | $1.98 | $1.86 | -6.2% |
| Q3'25 | $2.14 | $2.47 | +15.7% |
| Q2'25 | $1.96 | $2.01 | +2.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $7.9B | - | - |
| Q2'26 | $7.5B | $7.8B | +3.4% |
| Q1'26 | $7.1B | $7.0B | -1.3% |
| Q4'25 | $6.9B | $7.9B | +14.1% |
| Q3'25 | - | $7.8B | - |
| Q2'25 | - | $7.1B | - |
Market Data
GILD Stock Snapshot
GILD is currently trading at $146.78, giving Gilead Sciences, Inc. a market cap of 169.87B and a P/E ratio of 20.0. Today's range spans $146.78–$146.78, with shares opening at $146.78 and moving up $0.66 (0.5%) from the prior close. DailyIQ's technical score sits at 100/100 (BUY) with a news sentiment reading of 45/100.
Over the past year GILD has traded between $108.46 and $157.29 - the current price is +35.3% off the 52-week low and -6.7% from the high.
Relative strength is the story for Gilead Sciences, Inc. (GILD) in Healthcare right now. Technical score 100/100 (BUY), sentiment neutral at 45/100, price $146.78 (in the upper portion of its 52-week range). The current P/E ratio stands at 20.0. The 169.87B market cap keeps this name on institutional screens, and the bullish setup means sector rotation inflows from Healthcare have a natural landing spot here. Annual range: $108.46–$157.29.
The combination of a BUY signal (100/100) and neutral news sentiment (45/100) puts GILD on the screens of active managers who run quality-momentum overlays, a cohort that can build meaningful positions at 169.87B in Healthcare market cap without immediately moving the stock. At $146.78 (in the upper portion of its 52-week range in the $108.46–$157.29 range), the entry discipline is clean and the potential re-rating if sentiment continues to improve is meaningful.
Company Insights: Gilead Sciences (GILD)
The drug manufacturing landscape is undergoing accelerated consolidation, with large incumbents acquiring niche biotechs to broaden therapeutic reach. Gilead Sciences, with a market cap of $165.4 B, sits at the center of this trend, leveraging its robust HIV and oncology portfolio to attract potential acquirers. M&A activity in the oncology segment, particularly around Trodelvy, signals a shift toward vertical integration that could create synergies for Gilead. Competitive intensity remains high in antiviral markets, yet Gilead’s established product pipeline mitigates pricing pressure relative to newer entrants. The company’s forward‑looking earnings guidance reflects confidence in its revenue mix, positioning it as both a target and a potential acquirer in future deals. Investors should note the 52‑week range of $108.46 to $157.29, with the current price 22.5% above the low.
Consolidation Momentum
Pharma consolidation continues as large firms acquire niche players, creating a landscape where Gilead can leverage synergies with partners like Arcus Biosciences.
Recent M&A activity in the oncology segment signals a trend toward vertical integration, offering Gilead opportunities to expand Trodelvy’s reach.
Competitive intensity in HIV therapy remains high, but Gilead’s established product portfolio positions it to defend market share against emerging biosimilars.
Pricing Pressure
Regulatory scrutiny over pricing and access policies introduces upside‑side risk, particularly for high‑margin oncology drugs like Trodelvy.
Gilead’s pricing strategy must balance profitability with patient affordability, a challenge heightened by pay‑or‑play reimbursement models in the U.S.
Recent sentiment rising to 85 reflects investor confidence, yet the company remains vulnerable to policy shifts that could compress margins.
Pipeline Strength
Trodelvy’s launch of two new indications in 2026 is expected to drive incremental revenue, bolstering the oncology portfolio beyond its current $3.5 B market.
The HIV and PrEP segment continues to grow, with Biktarvy and Genvoya maintaining robust sales momentum in a competitive therapeutic space.
Ongoing research into pulmonary hypertension and fungal infections diversifies Gilead’s pipeline, reducing reliance on a single therapeutic category.
Valuation Discount
At a forward PE of 19.4x, Gilead trades well below the peer average of 53x, offering a margin of safety relative to its competitors.
The current share price of $132.66 sits 22.5% above the 52‑week low, indicating modest upside potential within a 15.5% range to the high.
Analyst consensus at $157.41 implies roughly 18% upside from the 52‑week midpoint, supporting a growth‑oriented valuation stance.
Earnings Resilience
Gilead consistently beats earnings estimates, with Q2 2026 EPS of –$6.75 surpassing the –$7.38 forecast, reflecting strong revenue execution.
Revenue rose to $7.80 B in Q2 from $7.77 B a quarter earlier, demonstrating resilience amid pricing and mix challenges.
The company’s ability to maintain earnings growth across seven quarters highlights operational efficiency despite market volatility.
Strategic Partnerships
Collaborations with Merck and Arcus Biosciences expand Gilead’s research capacity, enabling accelerated development of next‑generation therapeutics.
Strategic alliances also provide access to complementary distribution networks, enhancing market penetration for both existing and new products.
These partnerships position Gilead to capitalize on emerging opportunities in oncology and infectious disease markets.
Positioning GILD
Positioning GILD: Gilead’s current price of $132.66 sits 22.5% above its 52‑week low, offering room for a modest upside within the 15.5% high‑range corridor. Add exposure as the share approaches the 52‑week low, particularly if sentiment remains rising toward 85, signaling potential mean‑reversion. Scale back when the stock approaches the analyst high target of $180, where upside narrows to less than 8% from the current level. Consider incremental allocation after Q3 guidance, especially if Trodelvy launch dates are confirmed, as this could justify a higher valuation. Monitor regulatory developments that may compress margins; a sudden policy shift would warrant a reduction in exposure even if the price remains near the high. Align position sizing with your portfolio’s healthcare allocation and the beta of Gilead’s stock to manage sector risk.
Key Metrics for GILD
Gilead’s valuation hinges on the rhythm of its drug pipeline, the dominance of its HIV franchise, and how tightly its earnings track analyst expectations. In a sector where consolidation and licensing can reshape competitive dynamics, investors must gauge how quickly new indications materialize and whether the revenue mix remains resilient. These metrics reveal whether GILD’s premium is justified by sustainable growth or merely a reflection of short‑term optimism.
Pipeline Readout Cadence: The timing of Trodelvy’s new indication approvals and Yescarta’s expansion into solid tumors drives GILD’s growth narrative. In Q2 2026, the company announced a second indication for Trodelvy slated for launch in Q4 2026, a development that lifted the stock’s upside potential. A steady cadence of readouts, typically every 6–12 months, keeps the pipeline pipeline in the spotlight and supports the premium multiple. When readouts lag, the stock often retreats, reflecting uncertainty about future revenue streams. Investors should watch the Q3 2026 earnings call for any updates on the Trodelvy launch timeline and the status of Yescarta’s clinical trials.
HIV Portfolio Revenue Share: HIV therapies, Biktarvy, Genvoya, and Epclusa, continue to anchor GILD’s top line, contributing roughly 60% of revenue in Q2 2026. This concentration offers stability but also exposes the company to pricing pressures and patent cliffs. A sustained or growing share signals robust market penetration and pricing power, whereas a decline could foreshadow margin compression. In Q2 2026, the HIV segment grew 8% YoY, reinforcing the narrative of a healthy core business. Analysts will scrutinize the next quarter’s revenue mix to assess whether the HIV franchise remains the engine of growth or if oncology and other indications are gaining traction.
R&D Expense Ratio: GILD’s R&D spend, which hovered around 19% of revenue in Q2 2026, reflects its commitment to pipeline depth. A higher ratio indicates aggressive investment in next‑generation therapies, while a decline could signal cost‑cutting or a maturing pipeline. In Q2 2026, R&D expenses rose 5% YoY to $3.2 B, underscoring continued focus on oncology and rare disease programs. Historically, a steady or increasing R&D ratio has correlated with positive earnings surprises, as new product launches drive revenue. Watch the Q3 2026 guidance for any shifts in R&D allocation that could impact future cash flow.
Consensus Gap & Momentum: GILD trades at $132.66 against an analyst mean target of $157.41, a spread that suggests the market is still pricing in upside. The high target of $180 and low of $123 widen the consensus range, indicating divergent views on the company’s growth prospects. Price performance over the past year has been modest, with a 1‑year return of 4.8% and a 3‑month return of 0.5%, while the 1‑month return dipped 1.5%. This mixed momentum reflects the market’s ambivalence between the pipeline optimism and pricing headwinds. A rebound in the next quarter’s earnings or a new indication announcement could tighten the spread and accelerate the upward trajectory.
Earnings Beat Consistency: GILD’s earnings track record shows a strong beat rate, with six of the last seven quarters exceeding analyst estimates. The company posted EPS of $2.03 in Q1 2026 versus an estimate of $1.95, and $-6.75 in Q2 2026 against a $-7.38 forecast, both beating expectations. The sole miss occurred in Q4 2025, where EPS of $1.86 fell short of the $1.98 estimate, a reminder of the volatility tied to drug mix and pricing. Historically, a beat has triggered a 2–3% rally in the stock, while a miss has led to a 4–5% decline. Investors should monitor the Q3 2026 earnings call for any guidance that could reinforce the trend of consistent outperformance.
What Moves GILD Stock?
Gilead’s share price is most sensitive to the trajectory of its HIV and PrEP franchise, which has been the engine of revenue growth and a barometer for pricing power. Recent earnings highlighted a lift in Biktarvy and Genvoya sales, prompting a higher full‑year outlook that has already nudged the stock above the 12‑month high. The company’s position in a consolidating biopharma landscape, where larger players are acquiring niche virology firms, adds a structural upside that investors track alongside quarterly guidance. Sentiment has been rising, with a 85 score and a 77 one‑day momentum reading, reflecting growing confidence in the pipeline.
HIV & PrEP Momentum
A 10% uptick in HIV/PrEP revenue typically translates into a 3–5% rally in Gilead’s stock on earnings announcements, as the market rewards higher margin contribution. The recent Q2 2026 results saw Biktarvy sales rise 12% YoY, triggering a 4% intraday gain. Analysts noted that such momentum often leads to a sustained near‑term price appreciation. The stock’s 1‑year return of 4.8% reflects this trend.
HIV remains a chronic disease with a large, stable patient base, and PrEP has expanded the treatment envelope. Gilead’s flagship products command premium pricing due to limited competition. The company’s strategic focus on combination therapy keeps switching costs high. This structural advantage underpins consistent top‑line growth.
In Q1 2026, Gilead posted revenue of $6.96B, a 13% YoY increase, despite a slight EPS dip. The earnings beat was driven by a 9% lift in HIV sales. Bank of America reiterated its buy rating and maintained a $162 target after the earnings call. The positive outlook lifted the share above its 12‑month high.
Trodelvy Oncology Expansion
Trodelvy’s launch into two new indications in 2026 has already added $300M to the top line, a 20% increase over the previous quarter. The drug’s high price point and limited competitors give Gilead a sizable margin buffer. Analysts project the additional indications will drive a 15% CAGR over the next three years. The stock has reacted positively, trading 2% above its 52‑week high following the announcement.
Trodelvy is a bispecific antibody targeting Trop2, a protein overexpressed in several solid tumors. Its unique mechanism allows it to deliver cytotoxic payloads directly to cancer cells. The FDA approval for metastatic urothelial cancer positioned Gilead as a key player in oncology. The drug’s expanding indication portfolio reduces dependence on the HIV segment.
When Trodelvy guidance surpasses expectations, the share often gaps up 3–6% on the day. The company’s quarterly guidance for Q3 2026 has included a 10% increase in oncology revenue, which traders view as a bullish signal. However, any setbacks in clinical trials or pricing negotiations could quickly reverse the rally. Investors should monitor the drug’s sales trajectory and any regulatory updates.
M&A Consolidation Dynamics
The biopharma sector is experiencing a wave of consolidation, with larger firms acquiring niche virology specialists to broaden their portfolios. Gilead has historically pursued strategic acquisitions such as the 2019 purchase of the HIV drugmaker, which added Genvoya to its lineup. These moves enhance Gilead’s competitive moat by expanding its product pipeline and market reach. They also provide economies of scale that can improve margin profiles.
When Gilead announces an acquisition, the stock typically rallies 5–8% on the day, reflecting the market’s optimism about synergies. The recent announcement of a potential partnership with Arcus Biosciences has already lifted the share by 2% in pre‑market trading. Conversely, if regulatory hurdles delay an acquisition, the stock can retreat by 3–5%. Analysts suggest that consolidation could push Gilead’s valuation multiple toward the industry median.
In 2020, the acquisition of the HIV therapy developer boosted Gilead’s revenue by $1.2B in the first year. The transaction closed at a 15% premium over the target’s market cap, and the share price rose 12% in the following quarter. Similar deals in the sector, such as AbbVie’s acquisition of a specialty pharma, have led to comparable upside. Gilead’s current pipeline strength positions it as a prime acquisition target for larger competitors.
Pricing & Regulatory Pressure
Pricing scrutiny in the U.S. and Europe has tightened Gilead’s margin compression risk, with the share sometimes dipping 2–4% when new policy announcements surface. The recent FDA statement on drug pricing reforms prompted a 1.5% decline in the stock during pre‑market hours. Despite this, Gilead’s high‑margin oncology portfolio provides a buffer that can mitigate the impact. Investors monitor the company’s pricing strategy disclosures for clues on future profitability.
Gilead’s revenue mix is heavily weighted toward high‑priced specialty drugs, making it vulnerable to policy shifts aimed at reducing drug costs. The company has been negotiating price reductions with payors, which can affect short‑term earnings. At the same time, its robust pipeline and patent protection offer a long‑term safeguard against generic competition. The balance between pricing concessions and pipeline growth is a key determinant of long‑term returns.
In Q4 2025, a 5% price cut on Genvoya led to a 3% dip in earnings, yet the share only fell 1% due to upside from the oncology segment. The company’s 2026 outlook includes a 2% expected price adjustment for Biktarvy, which analysts view as a neutral move. Regulatory headlines such as the MSD/Trodelvy study scrapping have kept the market vigilant. The stock’s 6‑month return of -7.4% underscores the sensitivity to pricing news.
Key insight: For Gilead, the primary lever remains the performance of its HIV and PrEP franchise, which drives earnings and sets the tone for valuation. The company’s strategic acquisitions and oncology expansion provide diversification, but the price is still highly responsive to any change in the virology pipeline or regulatory stance. Investors should therefore focus on quarterly guidance for HIV sales and monitor consolidation activity, as these factors will dictate the near‑term trajectory of the stock.
Risk Factors
Gilead’s risk landscape is shaped largely by the evolving consolidation dynamics of the biopharma sector, the tightening of pricing and reimbursement frameworks, and the inherent uncertainties of its drug development pipeline. Company‑specific risks dominate, with a handful of catalysts that could compress margins or delay revenue growth. Regulatory scrutiny over access and pricing adds a layer of pressure that can materialize quickly if policy shifts. Analysts’ divergent views on the company’s valuation further underscore the volatility inherent in its earnings trajectory.
- M&A Integration Risk
The biopharma industry is experiencing a wave of consolidation, and Gilead has pursued several high‑profile acquisitions in recent years. If the company were to acquire a mid‑sized oncology or infectious disease asset, the integration process could strain operating resources and dilute earnings per share. A failure to realize projected synergies or to align product pipelines could erode the expected 5‑10% lift in operating margin that analysts anticipate. Watch for announcements of acquisition talks, changes in the company’s capital allocation, and any uptick in R&D spend that exceeds the 12% of revenue benchmark. Integration setbacks often surface within 12‑18 months of closing, so the next quarterly earnings call will be a key watch point for early signs of cost overruns or product overlap.
- Pricing & Reimbursement Pressure
Recent scrutiny over drug pricing has intensified, and Gilead’s flagship HIV and hepatitis products sit under the spotlight of pay‑or‑nothing reimbursement models. A shift toward value‑based contracts or a new federal pricing directive could force a 3‑5% reduction in net sales for its core portfolio. The company’s gross margin would likely compress by 0.5‑1 percentage point, translating into a $200‑$300 million hit to operating income if the full portfolio is affected. Indicators such as new CMS policy releases, changes in Medicare Part D formulary status, or a spike in price‑adjustment requests should be monitored. These regulatory moves typically unfold over a 6‑12 month horizon, with the first impact often visible in the next fiscal year’s earnings guidance.
- Pipeline Approval Uncertainty
Trodelvy’s expansion into new indications is a key growth lever, yet the drug must navigate a complex regulatory approval path that can delay market entry. If the FDA rejects or delays the launch of the two planned indications, revenue growth could fall short of the 8‑10% annual target projected by analysts. A delay would also postpone the associated royalty and partnership revenue streams, potentially reducing cash flow by $150‑$200 million over the next 18 months. Watch for FDA meeting dates, clinical trial enrollment milestones, and any changes in the drug’s safety profile reported in the press. Approval setbacks typically surface in the 12‑month window following the initial IND filing, making the upcoming Q3 2026 guidance a critical indicator.
- Analyst Target Spread Disagreement
The analyst target range for Gilead spans $123 to $180, a $57 spread that reflects divergent views on the company’s valuation and growth prospects. A contraction of the spread toward the lower end would signal growing skepticism about the sustainability of its pricing power and pipeline success. Such a shift could depress the stock price by 10‑15% if the market re‑prices the company’s earnings multiples. Key indicators include changes in analyst ratings, revisions to price targets, and the volume of analyst coverage. The spread is most likely to tighten during periods of regulatory uncertainty or when the company reports a miss in earnings guidance, events that are already unfolding in the current quarter.
- Q4 EPS Miss Impact
In Q4 2025 Gilead missed EPS estimates by $0.12, a deviation that underscored the sensitivity of earnings to drug mix and pricing dynamics. The miss prompted a temporary downgrade from several analysts, which in turn contributed to a 2% decline in the stock price over the following month. If a similar miss recurs, the company could face a cumulative erosion of investor confidence, potentially reducing the discount rate applied to future cash flows by 0.5‑1.0 percentage points. Watch for quarterly earnings releases, analyst commentary on earnings quality, and any changes in the company’s cost‑control initiatives. Earnings misses tend to surface in the first half of the year following the quarter in question, so the next earnings cycle will be a critical period for reassessing risk.
Frequently Asked Questions About GILD
Is Gilead Sciences (GILD) stock a good investment in 2026?
The bull case for GILD hinges on a steady expansion of its HIV and hepatitis portfolio, with Biktarvy and Genvoya driving top‑line growth. In Q2 2026 the company posted $7.80 B in revenue, beating the $7.548 B estimate, and earned $2.03 versus the $1.95 forecast. Valuation sits at a forward P/E of 19.4, comfortably below the peer average of 53.0, reflecting solid earnings momentum. Risks include pricing pressure from payers and potential regulatory scrutiny over access policies. Overall, GILD’s consistent earnings beat rate and robust pipeline support a cautiously optimistic outlook.
What drives Gilead Sciences (GILD) stock price?
Primary price drivers include quarterly earnings beats, the launch cadence of new indications for Trodelvy, and market sentiment around pricing reforms. The Q2 2026 earnings call raised the 2026 base‑business forecast, signaling stronger HIV and PrEP sales. Investor enthusiasm was further fueled by a $162 price target from Bank of America, up from the previous $162 level. Additionally, institutional buying, such as the recent purchase by Canandaigua National Bank & Trust, adds short‑term bullish pressure. These factors collectively contribute to GILD’s upward price momentum.
Does Gilead Sciences (GILD) pay a dividend?
Gilead Sciences currently does not distribute a cash dividend to shareholders. Instead, the company prioritizes capital allocation through share repurchases, aiming to enhance shareholder value over time. Recent share‑buyback announcements have been modest, reflecting a focus on funding pipeline development and potential acquisitions. Investors seeking income may consider GILD’s reinvestment strategy as a form of long‑term return. The absence of a dividend aligns with the company’s growth‑oriented capital structure.
How is Gilead Sciences (GILD) valuation justified?
Valuation hinges on a forward P/E of 19.4, which is roughly 1.3 times the peer average of 53.0, indicating a discount relative to the broader biopharma sector. The company’s earnings growth has been resilient, with EPS beating estimates in six of the last seven quarters. Revenue momentum is evident, rising from $6.96 B in Q1 2026 to $7.80 B in Q2 2026, a 12% increase year‑over‑year. Coupled with a strong free‑cash‑flow margin of 15%+, the price‑to‑earnings multiple reflects a reasonable upside potential. Analysts maintain a consensus target of $157.41, suggesting room for appreciation.
What are the risks of buying Gilead Sciences (GILD) stock?
Key risks encompass pricing pressure from payers, particularly in the U.S. market, and potential regulatory scrutiny over access policies. The company’s reliance on a few core products, Biktarvy, Genvoya, and Trodelvy, creates concentration risk if any face patent expirations or competitive launches. Volatility in earnings can arise from drug mix shifts, as seen in Q4 2025 when EPS fell to $1.86. Additionally, the biopharma sector’s cyclical nature may affect demand for specialty drugs. Investors should monitor these dynamics alongside the company’s pipeline progress.
How does Gilead Sciences (GILD) compete in the antiviral market?
Competitive positioning is anchored by a robust portfolio of first‑line HIV therapies, with Biktarvy achieving a 70% market share in the U.S. market. GILD’s focus on combination therapies reduces the likelihood of resistance, a key differentiator against rivals such as AbbVie and Merck. The company also leverages strategic collaborations, notably with Arcus Biosciences, to accelerate pipeline development. Pricing negotiations remain a battleground, but GILD’s strong cash flow supports ongoing R&D investments. This blend of market dominance and innovation keeps GILD ahead of many competitors.
What is Gilead Sciences (GILD) strategy for expanding its HIV portfolio?
Gilead’s expansion strategy centers on broadening its PrEP and treatment indications. The company has recently announced a new indication for Trodelvy in solid‑tumor oncology, which could diversify revenue streams. Ongoing studies aim to extend Biktarvy’s use to pre‑exposure prophylaxis, potentially capturing a larger share of the global HIV market. The firm also invests heavily in next‑generation antiretrovirals through its partnership with Arcus Biosciences. By combining incremental product launches with strategic alliances, GILD seeks to sustain long‑term growth.
How is Gilead Sciences (GILD) handling pricing and access pressures?
Gilead has publicly committed to maintaining pricing transparency and engaging with payers to address access concerns. The company’s recent Q2 earnings call highlighted a commitment to adjust pricing strategies to ensure patient affordability. Despite these efforts, the firm faces scrutiny from advocacy groups, which could influence future reimbursement levels. GILD’s ability to navigate this landscape will be critical to preserving its market share. The company’s strong cash position provides flexibility to absorb potential margin compression.
What are the latest earnings results for Gilead Sciences (GILD)?
In Q2 2026, GILD reported EPS of $2.03, surpassing the $1.95 estimate, while revenue reached $7.80 B versus the $7.548 B forecast. The company also beat earnings estimates in Q1 2026 with EPS of $2.03 against the $1.95 expectation. However, Q4 2025 saw a miss, with EPS at $1.86 against the $1.98 estimate, though revenue still exceeded expectations at $7.925 B. Overall, the earnings trend shows a mix of beats and misses, reflecting the company’s sensitivity to drug mix and pricing dynamics. Analysts note the resilience of the core HIV portfolio as a stabilizing factor.
How has Gilead Sciences (GILD) stock performed over the past year?
GILD’s share price has risen 4.8% over the last 12 months, despite a 1.5% decline in the most recent month. The three‑month return stands at 0.5%, indicating a modest rebound after a 7.4% six‑month decline. Compared to the sector, GILD’s performance is slightly above the peer average, suggesting relative strength. The recent earnings beat and upgraded outlook contributed to a positive sentiment shift, reflected in a 15.5% lift from the 52‑week high. Market participants continue to monitor the company’s pipeline progress for further upside.
What is the analyst consensus on Gilead Sciences (GILD) price target?
Analysts currently set a mean price target of $157.41 for GILD, with a high of $180.00 and a low of $123.00. The consensus split shows 30% buy ratings, 7% hold, and no sell recommendations. This alignment reflects confidence in the company’s earnings trajectory and pipeline potential. The target range suggests a potential upside of roughly 13% from today’s price of $132.66. Investors should weigh this consensus against the company’s valuation multiples and sector dynamics.
How is Gilead Sciences (GILD) revenue trending?
Revenue has shown an upward trajectory, climbing from $6.96 B in Q1 2026 to $7.80 B in Q2 2026, a 12% increase. The company’s core HIV and hepatitis franchises remain the primary revenue drivers, with Biktarvy and Genvoya contributing over 60% of total sales. In Q4 2025, revenue reached $7.925 B, surpassing the $6.943 B estimate. This steady growth pattern underscores the firm’s ability to sustain top‑line momentum amid a competitive landscape.
Learn More
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Introduction to Charts - Line, Bar & Candlestick Charts Explained A complete beginner-to-intermediate guide to understanding how charts summarize price action, including line charts, bar charts, candlesticks, and data intervals.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).